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1012-131 Statins Decrease Mortality in Patients Undergoing 
Percutaneous Coronary Intervention With Left 
Ventricular Dysfunction
Michael J. Lipinski, Robert E. Martin, Michael J. Cowley, Evelyne Goudreau, Walter N. 
Malloy, George W. Vetrovec, Virginia Commonwealth University Health System, 
Richmond, VA
Background
While statins have been shown to decrease mortality in a population that went on to
develop heart failure after beginning statin therapy, uncertainty remains whether statins
are appropriate for patients with pre-existing left ventricular (LV) dysfunction. The goal of
this study was to determine whether statin therapy improved survival in patients with LV
dysfunction undergoing percutaneous coronary intervention (PCI).
Methods
We retrospectively evaluated consecutive patient procedures performed in our institution
from 1996 through 1999. To be included, patients had to have a technically adequate
angiographic LV gram with a calculated EF<50%. Patients with prior CABG were
excluded. Mortality data was retrieved using the United States Social Security Death
Index. Follow-up ranged from 3.5 to 6.5 years. 
Data Analysis
Cox Hazard regression, student T-tests, Kaplan-Meier survival analysis, and ROC curve
analysis was performed to compare mortality and variables between the different sub-
groups. Means are provided with ± Std Dev and p-values less than 0.05 were considered
significant.
Results 
A total of 244 patients with an average EF of 39% ± 9.8% fulfilled our criteria. Mean age
was 57.5 ±12 years, 68% were males, co-morbidities included 82% with HTN, 68% had
hypercholesterolemia, and 36% had DM. Sixty-one percent underwent PCI for a recent
MI, 68% percent of our population underwent PCI with stenting, and 64% were dis-
charged on statins. During follow-up, 27% of our population died. Of the patients taking
statins, 96% had hypercholesterolemia while 90% of patients with hypercholesterolemia
were taking statins. Statins significantly improved survival at 1, 3, and 5 years (97% vs
84%, p<.001; 93% vs 72%, p<.00001; 87% vs 63%, p<.00001). Statin survival benefits
persist regardless of MI history and EF. Statin use, along with age, calculated EF, diuretic
use, and renal disease, was found to be significant on Cox Hazard Regression.
Conclusion.
In our retrospective analysis on patients with left ventricular dysfunction undergoing PCI,
hypercholesterolemic patients discharged on statins had improved survival compared to
patients not taking statins with normal cholesterol levels.
1012-132 Atorvastatin Affects the Expression of Both 
Endothelium- and Liver-Derived Components of 
Thrombosis/Fibrinolysis System and Endothelial 
Function in Patients With Congestive Heart Failure
Dimitrios Tousoulis, Charalambos Antoniadis, Maria Kotsopoulou, Erini Bosinakou, 
Costas Tentolouris, Christos Pitsavos, Kyriakoula Marinou, Stella Brilli, Athanasios 
Trikas, Christodoulos Stefanadis, Athens University Medical School, Hippokration 
Hospital, Athens, Greece
Introduction: Congestive heart failure (CHF) is characterised by endothelial dysfunction
and increased thrombogenecity. We investigated the effect of atorvastatin on endothelial
function and on plasma levels of antithrombin III (ATIII), proteins C and S, factors V and
VII, von Willebrand factor (vWF), tissue plasminogen activator (tPA) and plasminogen
activator inhibitor 1 (PAI-1) in patients with CHF.
Methods: Thirty-five patients with CHF (NYHA II-IV) were randomized to receive atorv-
astatin 10mg/day (n=17) or no statin (n=18) for 4 weeks. Forearm blood flow was mea-
sured by venous occlusion strain-gauge plethysmography. Endothelium dependent
dilation (EDD) and endothelium independent dilation (EID) were expressed as the %
change of flow from baseline to the maximum flow during reactive hyperemia or after
sublingual nitroglycerin administration respectively. Plasma levels of thrombosis/fibrinoly-
sis components were determined with ELISA.
Results: Atorvastatin improved EDD (42.44±4.5 to 83.7±8.5%, p<0.01), decreased
plasma levels of tPA (15.5±2.2 to 12.3±1.6 ng/ml p<0.05), ATIII (82±3 to 74±4%, p<0.05),
prtC (88±6 to 64±6%, p<0.01), fV (126±8 to 95±7%, p<0.01) and PAI-1 (3.02±0.39 to
1.96±0.34 IU/L, p<0.05), while it did not affect EID (65±8 to 53±6% p=ns) and levels of
fVII (81±8 to 66±7% p=ns), vWF (135±13 to 123±19% p=ns) and prtS (93±5 to 95±8%
p=ns). EDD and EID remained unchanged in controls (from 48±5 and 67±8 to 45±5%
and 61±7% respectively p=ns for both). In control group, no significant change was
observed in levels of ATIII (85±4 to 88±3%,p=ns), prtC(84±6 to 84±5%,p=ns), fV(131±10
to 122±9%,p=ns), fVII(78±12 to 69±9%,p=ns), vWF (151±19 to 135±38%, p=ns), prtS
(100±8 to 96±6%, p=ns), tPA(13.2±1.5 to 11±2 ng/ml, p=ns) and PAI-1(2.64±0.38 to
3.25±0.34, p=ns).
Conclusions: Short-term treatment with atorvastatin improves endothelial function and
reduces plasma levels of tPA, PAI-1, antithrombin III, protein C and factor V, in patients
with CHF, suggesting that atorvastatin may affect the expression of both endothelium-
and liver-derived components of thrombosis fibrinolysis system, beyond its effect on vas-
cular endothelium in these patients.
1012-133 Statin Therapy Can Improve Cardiac Function and 
Survival After Heart Failure in Rats
Sahoko Ichihara, Akiko Noda, Akira Yamada, Tomoko Kato, Kohzo Nagata, Mitsunori 
Iwase, Toyoaki Murohara, Mitsuhiro Yokota, Nagoya University Graduate School of 
Medicine, Nagoya, Japan
Background: Congestive heart failure has been shown to be related to an increase in oxi-
dative stress. We hypothesized that statin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA
reductase, prevents the progression from compensated left ventricular (LV) hypertrophy
to heart failure and improves survival with a reduction in oxidative stress in a rat model.
Methods and Results: Dahl salt-sensitive (DS) rats fed an 8% NaCl diet from 7 weeks of
age were treated with pravastatin 50 mg/kg/day or 100 mg/kg/day from 7 or 12 weeks of
age. At 18 weeks of age, untreated DS rats exhibited prominent concentric LV hypertro-
phy, and diastolic and systolic dysfunction was seen by echocardiography. We found that
treatment with statin did not affect serum lipid levels or blood pressure. Treatment with
pravastatin 100 mg/kg/day (but not 50 mg/kg/day) from 7 weeks of age attenuated hyper-
tensive LV hypertrophy and markedly improved indices of diastolic function (peak nega-
tive myocardial velocity gradient); -2.25 ± 0.77/s to -3.28 ± 0.57/s, (p < 0.05) and systolic
function (LV fractional shortening); 28.5 ± 1.5% to 35.2 ± 1.2%, (p < 0.05), and also
improved survival rate (40.7% to 83.3%, p < 0.01). Treatment with statin ameliorated glu-
tathione redox status (p < 0.05) and improved inflammatory responses. We also found
that treatment with pravastatin (100 mg/kg/day only) from 12 weeks of age brought about
the same benefit for cardiac function and survival. Conclusion: Statin therapy before and
even after the development of hypertensive LV hypertrophy improved LV phenotypic
changes, diastolic and systolic function, and survival in a rat hypertensive heart failure
model.
1012-134 Direct, Dose-Dependent Antifibrotic Effects of 
Atorvastatin in Human Cardiac Fibroblast Cell Culture
Henry Krum, Jenny Martin, Rachel Denver, Salvatore Pepe, Monash University, NHMRC 
CCRE in Therapeutics, Melbourne, Victoria, 3004, Australia
Background: HMGcoA reductase inhibitors (statins) may have beneficial effects on car-
diac remodelling post myocardial injury. These effects appear to be additional to the lipid-
lowering and anti-ischaemic actions of these agents. As pathological deposition of extra-
cellular matrix (fibrosis) is a key component of remodelling post myocardial injury, we
sought to determine whether these agents could directly inhibit matrix production in-vitro,
as well as mechanisms by which these effects may occur.
Methods: The effect of atorvastatin (ATV, 10-8M-10-5M) was examined in human cardiac
fibroblast cell culture after stimulation with the known pro-fibrotic factors angiotensin II
(AII, 10-7 M) and transforming growth factor-β (TGF-β). Non-stimulated, non-treated wells
served as controls. Collagen production was estimated by [3H]-proline incorporation (P).
Results: AII and TGF-β increased [3H]-P by 38±17% and 90±34% respectively. ATV
caused a dose-dependent reduction in [3H]-P (% decrease c/f AII alone: 10-8M, -
44+19%; 10-7M, -44+14%; 10-6M, -55+14%; 10-5M, -78+13%; p<0.05; % decrease c/f
TGF-β alone: 10-8M, -9+4%; 10-7M, -20+12%; 10-6M, -46+6%; 10-5M, -67+15%; p<0.05).
ATV similarly reduced AII- and TGF-β-induced [3H]-P in a dose-dependent manner,
p<0.05. Both AII and TGF-β significantly increased α(1) pro-collagen mRNA by 22 and
300% respectively; an effect that was blocked by ATV (% decrease c/f. AII alone: 10-5M: -
54+23%; % decrease c/f TGF-β alone: 10-5M: -33±9.5%).
To determine whether these effects of statins were mediated by alterations in the pro-
fibrotic peptide, connective tissue growth factor (CTGF), we measured CTGF mRNA in
these studies. Both AII and TGF-β increased CTGF mRNA by 86±18% and 98±19%
respectively; this was significantly reduced by ATV (% decrease c/f AII alone: 10-5M: -
67%±18%; c/f TGF-β alone 10-5M: -44±13%).
Conclusions: We have demonstrated for the first time a direct, anti-fibrotic effect of
statins in human cardiac fibroblast cell culture, following stimulation with pro-fibrotic fac-
tors known to be important in cardiac remodelling post-myocardial injury. These actions
may contribute to the potential favourable anti-remodelling effects of statins.
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1013-113 Strain Rate and Strain Rate-Derived Time to Onset of 
Relaxation Can Be Used for the Early Detection of 
Impaired Myocardial Function in Asymptomatic Boys 
With Duchenne Muscular Dystrophy
Nickolaos D. Giatrakos, Maria Kinali, Francesco Muntoni, Petros Nihoyannopoulos, 
Hammersmith Hospital, NHLI, ICSM, London, United Kingdom, Dubowitz Neuromuscular 
Centre, Hammersmith Hospital, ICSM, London, United Kingdom
Background. Patients with Duchenne muscular dystrophy (DMD) frequently develop
dilated cardiomyopathy at the later stages of the disease. Strain rate (SR) has been used
to study ischeamia and cardiomyopathies and time to onset of regional relaxation (TR) by
SR imaging has been used to quantify regional myocardial function. The aim of this study
was to investigate the usefulness of SR and SR derived TR for the early detection of car-
diac involvement in young, asymptomatic patients with DMD which is critical to initiate
life-saving therapeutic interventions.
